We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Altered Ratios of p53 Isoforms Predict Response of Breast Tumors to Chemotherapy

By LabMedica International staff writers
Posted on 24 Nov 2022
Print article
Image: A micrograph showing cells with abnormal p53 expression (brown) in a brain tumor (Photo courtesy of Wikimedia Commons)
Image: A micrograph showing cells with abnormal p53 expression (brown) in a brain tumor (Photo courtesy of Wikimedia Commons)

Alterations in the distribution of p53 isoforms are predictive of the likelihood that a breast tumor will respond to treatment with the chemotherapeutic drug doxorubicin.

The regulatory protein p53 is often mutated in human cancers. In vertebrates, the p53 protein complex is vital for prevent cancer formation. As such, p53 has been described as "the guardian of the genome" because of its role in conserving stability by preventing genome mutation.

Investigators at the Hunter Medical Research Institute (New Lambton Heights, Australia) have shown in previous studies that p53 isoform expression was altered in breast cancer and related to prognosis. In particular, a high delta40p53:p53alpha ratio was associated with worse disease-free survival.

In the current study, the influence of altered delta40p53 and p53alpha levels on the response to standard of care DNA-damaging agents used in breast cancer treatment was evaluated.

Results revealed that a high delta40p53:p53alpha ratio caused cells to respond differently to doxorubicin and cisplatin treatments. Delta40p53 overexpression significantly impaired the cells’ sensitivity to doxorubicin through reducing apoptosis and DNA damage, whereas inhibition of delta40p53 had the opposite effect. Further, a high delta40p53:p53alpha ratio inhibited the differential expression of several genes following doxorubicin and promoted DNA repair.

Overall, these results suggested that the response of breast cancer cells to standard of care DNA-damaging therapies was dependent on the expression of p53 isoforms, which may contribute to outcomes in breast cancer.

Senior author Dr. Kelly Avery-Kiejda, associate professor of biomedical sciences and pharmacy at he Hunter Medical Research Institute, said, “One in eight women in Australia develop breast cancer and while there is a 92% survival rate, this does not take into account secondary cancers or metastasis, which are essentially incurable. If we can identify biomarkers that predict how well a patient will respond to certain therapies, we can then target the available therapies more effectively.”

The findings were published in the October 28, 2022, online edition of the journal Cell Death & Disease.

Related Links:
Hunter Medical Research Institute 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more